Literature DB >> 591642

Aminopyrine breath test in alcoholic liver disease and in patients on enzyme-inducing drugs.

K O Lewis, G Nicholson, P Lance, A Paton.   

Abstract

The 14C-aminopyrine breath test was used to measure liver function in 14 normal subjects, 16 patients with alcoholic cirrhosis, 14 alcoholics without cirrhosis, and 29 patients taking a variety of drugs. The normal value for the breath test was 8.6 +/- 1.5%, whereas it was significantly lower (5.1 +/- 3.8%) in patients with alcoholic cirrhosis. Higher than normal values were found in some alcoholic patients without cirrhosis and in patients receiving enzyme-inducing drugs, such as phenobarbitone. There was a significant correlation between serum gamma-glutamyltransferase and breath test in these groups. Some patients with alcoholic cirrhosis may also be capable of enzyme induction.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 591642      PMCID: PMC476640          DOI: 10.1136/jcp.30.11.1040

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  12 in total

1.  A new look at the measurement and interpretation of enzyme assays.

Authors:  G Ceriotti
Journal:  Ann Clin Biochem       Date:  1976-03       Impact factor: 2.057

Review 2.  Gamma-glutamyl transpeptidase.

Authors:  S B Rosalki
Journal:  Adv Clin Chem       Date:  1975       Impact factor: 5.394

Review 3.  Liver adaptation and injury in alcoholism.

Authors:  C S Lieber
Journal:  N Engl J Med       Date:  1973-02-15       Impact factor: 91.245

4.  Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis.

Authors:  G W Hepner; E S Vesell
Journal:  N Engl J Med       Date:  1974-12-26       Impact factor: 91.245

5.  Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy.

Authors:  A J Levi; S Sherlock; D Walker
Journal:  Lancet       Date:  1968-06-15       Impact factor: 79.321

6.  Isoenzyme patterns of serum alkaline phosphatase in ethanol-induced liver injury.

Authors:  J Brohult; L Sundblad
Journal:  Acta Med Scand       Date:  1973-12

7.  Serum -glutamyl transpeptidase activity in alcoholism.

Authors:  S B Rosalki; D Rau
Journal:  Clin Chim Acta       Date:  1972-06       Impact factor: 3.786

8.  Increase of ethanol, meprobamate and pentobarbital metabolism after chronic ethanol administration in man and in rats.

Authors:  P S Misra; A Lefévre; H Ishii; E Rubin; C S Lieber
Journal:  Am J Med       Date:  1971-09       Impact factor: 4.965

9.  Expiratory measurement of maximal amino-pyrine demethylation in vivo: effect of phenobarbital, partial hepatectomy, protacaval shunt and bile duct ligation in the rat.

Authors:  B H Lauterburg; J Bircher
Journal:  J Pharmacol Exp Ther       Date:  1976-02       Impact factor: 4.030

10.  Aminopyrine demethylation measured by breath analysis in cirrhosis.

Authors:  J Bircher; A Küpfer; I Gikalov; R Preisig
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

View more
  4 in total

1.  Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism.

Authors:  M Døssing; H Pilsgaard; B Rasmussen; H E Poulsen
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  [13C]methacetin breath test for evaluation of liver damage.

Authors:  K Matsumoto; M Suehiro; M Iio; T Kawabe; Y Shiratori; K Okano; T Sugimoto
Journal:  Dig Dis Sci       Date:  1987-04       Impact factor: 3.199

3.  Assessment of the cytochrome P-448 dependent liver enzyme system by a caffeine breath test.

Authors:  H Wietholtz; M Voegelin; M J Arnaud; J Bircher; R Preisig
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

4.  Breath 14CO2 after intravenous administration of [14C]aminopyrine in liver diseases.

Authors:  S Pauwels; A P Geubel; C Dive; C Beckers
Journal:  Dig Dis Sci       Date:  1982-01       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.